Clinilabs is a specialty CRO that provides clinical development services to pharmaceutical and biotechnology companies involved in the development of CNS and cardiovascular therapeutics. The Company offers a full portfolio of clinical contract research services, including project management, site recruitment, clinical and medical monitoring, as well as “back-end” services (data management, biostatistics, and medical writing).
In addition to the management of multicenter studies, Clinilabs conducts Phase I and proof-of-concept studies in any therapeutic area at the Company’s state-of-the-art, 60-bed unit in Manhattan. This unit offers an ideal location for timely recruitment of healthy volunteers, special populations (e.g., Japanese, renal impairment, hepatic impairment), and clinical populations.
The ability to execute polysomnographic (PSG), electroencephalographic (EEG), quantitative EEG, pharmaco EEG, electrocardiographic (ECG), thorough QT (TQT), and ambulatory blood pressure (ABP) studies is among Clinilabs’ strengths. The Company’s centralized reading of PSGs, EEGs, and ECGs in multicenter, domestic and global studies provides added value to its clients.
Established in 2001, Clinilabs has provided services to one third of the world's top 20 pharmaceutical companies, and has been involved in seven successful New Drug Applications (NDAs). Clinilabs is dedicated to providing high quality, prompt, and cost-effective services to its clients in the interest of delivering new therapeutics to those in need.
|
